Compare NRXP & ALIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRXP | ALIS |
|---|---|---|
| Founded | 2015 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.8M | 83.9M |
| IPO Year | N/A | 2025 |
| Metric | NRXP | ALIS |
|---|---|---|
| Price | $2.28 | $9.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $30.67 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 43.3K |
| Earning Date | 11-17-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $242,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $847.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $9.85 |
| 52 Week High | $4.48 | $9.97 |
| Indicator | NRXP | ALIS |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | N/A |
| Support Level | $2.00 | N/A |
| Resistance Level | $2.48 | N/A |
| Average True Range (ATR) | 0.17 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 35.95 | 0.00 |
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.